BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC) Insider Sells $118,143.90 in Stock

BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC - Get Free Report) insider Lai Wang sold 470 shares of the stock in a transaction on Tuesday, June 17th. The shares were sold at an average price of $251.37, for a total value of $118,143.90. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

Lai Wang also recently made the following trade(s):

• On Monday, June 16th, Lai Wang sold 1,177 shares of BeOne Medicines stock. The shares were sold at an average price of $266.40, for a total value of $313,552.80.
• On Friday, June 6th, Lai Wang sold 1,402 shares of BeOne Medicines stock. The stock was sold at an average price of $252.39, for a total value of $353,850.78.

BeOne Medicines Trading Down 0.5%

BeOne Medicines stock traded down $1.31 during trading on Wednesday, reaching $252.78. The company had a trading volume of 230,441 shares, compared to its average volume of 447,828. The business's 50-day moving average is $243.44. BeOne Medicines Ltd. - Sponsored ADR has a 52 week low of $141.31 and a 52 week high of $287.88. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.96 and a quick ratio of 1.71. The stock has a market capitalization of $27.69 billion, a price-to-earnings ratio of -67.95 and a beta of 0.30.

BeOne Medicines (NASDAQ:ONC - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The company reported $1.22 EPS for the quarter, topping the consensus estimate of ($0.71) by $1.93. BeOne Medicines had a negative return on equity of 7.55% and a negative net margin of 9.40%. The firm had revenue of $1.12 billion for the quarter, compared to the consensus estimate of $1.12 billion. On average, analysts predict that BeOne Medicines Ltd. - Sponsored ADR will post -5.82 earnings per share for the current year.

Analyst Upgrades and Downgrades

ONC has been the topic of a number of recent analyst reports. Sanford C. Bernstein set a $259.00 price target on shares of BeOne Medicines in a report on Thursday, March 13th. Royal Bank Of Canada dropped their target price on shares of BeOne Medicines from $312.00 to $311.00 and set an "outperform" rating on the stock in a report on Thursday, May 8th. TD Securities reaffirmed a "buy" rating and issued a $334.00 target price on shares of BeOne Medicines in a research report on Thursday, April 24th. Guggenheim boosted their target price on shares of BeOne Medicines from $348.00 to $350.00 and gave the company a "buy" rating in a research note on Thursday, May 8th. Finally, Macquarie raised their target price on BeOne Medicines from $259.00 to $313.00 and gave the stock an "outperform" rating in a research report on Friday, February 28th. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and an average target price of $319.00.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.